METHOD DEVELOPMENT AND VALIDATION OF IVACAFTOR IN BULK & PHARMACEUTICAL DOSAGE FORM BY UV-VISIBLE SPECTROPHOTOMETRY

被引:2
作者
Gautam, Ch V. S. [1 ]
Charan, K. Sai [1 ]
Swathi, B. [1 ]
Mounika, M. [1 ]
机构
[1] SSJ Coll Pharm, Dept Pharmaceut Anal & Qual Assurance, Hyderabad, Telangana, India
来源
INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES | 2019年 / 6卷 / 04期
关键词
Ivacaftor; Method development; Validation; Ultraviolet-visible spectrophotometry;
D O I
10.5281/zenodo.2637689
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Objective: The objective of the present work is to develop a simple, efficient, and reproducible spectrophotometric method for the quantitative estimation of drug - Ivacaftor in active pharmaceutical ingredient (API) form and in pharmaceutical dosage form Methods: The developed ultraviolet spectrophotometric method for the quantitative estimation of Cystic fibrosis drug Ivacaftor based on measurement of absorption at a wavelength maximum (lambda max) of 255 nm using Acetonitrile as solvent. Results: The method was validated in terms of, precision, linearity, accuracy, and robustness, LOD, LOQas per the ICH guidelines. The method was found to be linear in the range of 50-150% for Ivacaftor. The percentage recovery values were in the range of 99.9-100.9% for Ivacaftor at different concentration levels. Relative standard deviation for precision and intermediate precision results were found to be <2%. The correlation coefficient value observed for Ivacaftor drug substances was not <0.99, 0.99, respectively. Results obtained from the validation experiments prove that the developed method is quantified for the estimation of Ivacaftor drug substances. Conclusion: The developed method can be successfully applied for Ivacaftor routine analysis, quality control analysis, and also suitable for stability analysis of in API & its pharmaceutical dosage form as per the regulatory requirements.
引用
收藏
页码:7476 / 7481
页数:6
相关论文
共 4 条
  • [1] Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Potentiator VX-770 (Ivacaftor) Opens the Defective Channel Gate of Mutant CFTR in a Phosphorylation-dependent but ATP-independent Manner
    Eckford, Paul D. W.
    Li, Canhui
    Ramjeesingh, Mohabir
    Bear, Christine E.
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2012, 287 (44) : 36639 - 36649
  • [2] Janardhana Reddy VL, INT J RES PHARM SCI, V9, P1169
  • [3] Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects
    Kuk, Kelly
    Taylor-Cousar, Jennifer L.
    [J]. THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2015, 9 (06) : 313 - 326
  • [4] Sahil Kataria, ARTICLE VALIDATION A